Background: India is a low-middle income country and cost constraints affect use of emerging technologies in diabetes management. Ambulatory Glucose Profile(AGP) using Libre-pro(Abbott) to assess 14 days ambulatory blood glucose(BG) levels and glucose variability(GV) is used sparingly due to cost concern. Many physicians use interval analysis based on AGP data retrieval at 5-7 days to modify treatment and also evaluate its impact on BG levels at 14 days. However, there is little or no published data on this.

Aim: To assess whether treatment modifications based on interval analysis of daily glucose curves during AGP can improve glucose levels and reduce glucose variability METHOD We analyzed records of 40 type 2 diabetes(T2D) patients(27 men, 13 women, age 17-78 years) who had undergone AGP using Libre-pro and in whom interval analysis of daily BG curves was performed at 7 days. In these patients data was retrieved and analyzed at 7th day during AGP and treatment was modified based 0-7day data. AGP was continued and complete data was retrieved at 14th day. Comparison was made for average BG and for time in-, above- and below target range, before and after the 7th day treatment modifications.

Results: Analysis of AGP records showed a significant reduction in 7-14 days mean BG levels after intervention at 7th day as compared to 0-7 days mean(152.11±35.29 vs. 173.23±46.4mg/dl, p=0.025). Time in target range increased from 32.33±22.51% to 41.82±21.67% but was not statistically significant(p=0.059). Time above target range decreased significantly from 62.78±25.54% to 50.85±25.86%(p=0.041) while change in time below target range was non-significant(4.97±6.91% vs. 6.62±7.66%, p=0.32).

Conclusion: Treatment decisions based on Interval analysis of AGP data are effective in significantly reducing blood glucose levels and glucose variability in type 2 diabetes patients. Time in range also increased but was statistically not significant.


B.M. Makkar: Advisory Panel; Self; Abbott, AstraZeneca, Biocon, Boehringer Ingelheim Pharmaceuticals, Inc., Eris Lifesciences, Novartis AG, Novo Nordisk Inc., Sanofi, USV Private Limited. Speaker’s Bureau; Self; Janssen Pharmaceuticals, Inc. K. Soota: None. V. Gupta: Advisory Panel; Self; Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd. J.K. Sharma: None. G. Khurana: None. R. Chawla: None. S. Jaggi: None. H. Thacker: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at